Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-stage Liver Disease Scores Compared With Placebo

Caspase-mediated apoptosis and inflammation contribute to progression of liver disease. Emricasan is a pan-caspase inhibitor that reduced serum markers of apoptosis and liver inflammation in patients with hepatitis C and non-alcoholic steatohepatitis (NASH).

Source: Clinical Gastroenterology and Hepatology - June 15, 2018 Category: Gastroenterology Authors: Catherine T. Frenette, Giuseppe Morelli, Mitchell L. Shiffman, R. Todd Frederick, Raymond A. Rubin, Michael B. Fallon, Jason T. Cheng, Matt Cave, Saira A. Khaderi, Omar Massoud, Nikolaos Pyrsopoulos, James S. Park, James M. Robinson, Mason Yamashita, Alfr Source Type: research